Clinical TrialMay 4, 2026, 04:33 PM
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan
AI Summary
InflaRx N.V. announced new preclinical data showing izicopan, a next-generation oral C5aR1 inhibitor, has a favorable reactive metabolite profile in human liver microsomes. In a head-to-head in vitro study, izicopan demonstrated minimal reactive metabolite formation, while the comparator avacopan showed significantly higher levels of thiol adducts, consistent with more extensive oxidative bioactivation. These findings support a lower extent of reactive intermediate formation for izicopan, suggesting a differentiated profile within the C5aR inhibitor class with potential safety advantages.
Key Highlights
- Izicopan demonstrated minimal reactive metabolite formation in human liver microsomes.
- Avacopan showed higher levels of thiol adducts, indicating more extensive oxidative bioactivation.
- Differences in reactive conjugate peak areas exceeded 100-fold at 5 and 10 minutes.
- Differences remained approximately 10-fold at 20 and 40 minutes of incubation.
- These preclinical findings support a low level of bioactivation for izicopan.
- Results suggest a lower extent of reactive intermediate formation for izicopan.
- Izicopan does not inhibit the cytochrome P450 3A4 (CYP3A4) enzyme.
- Previous Phase 1 and Phase 2a studies showed izicopan was well tolerated with no safety signals.
Price Impact
More from IFRX